Pfizer’s Estimates Boosted at UBS on Viagra Ruling (PFE)
Pharmaceutical maker Pfizer Inc. ( PFE ) on Tuesday saw its earnings estimates raised by analysts at UBS.
The firm said it boosted its estimates for PFE through 2012, citing a recent district court ruling that preserved the company's blockbuster Viagra drug's exclusivity through 2019.
UBS maintained its "Buy" rating and $23 price target, which suggests a 25% upside to the stock's Monday closing price of $18.34.
Pfizer shares fell 17 cents, or -0.9%, in premarket trading Tuesday.
The Bottom Line
Shares of Pfizer ( PFE ) have a 4.36% dividend yield, based on last night's closing stock price of $18.34. The stock has technical support in the $16-$17 price area. If the shares can firm up, we see overhead resistance around the $20 price level.
Pfizer Inc. ( PFE ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
